JP2024524222A5 - - Google Patents
Info
- Publication number
- JP2024524222A5 JP2024524222A5 JP2023578940A JP2023578940A JP2024524222A5 JP 2024524222 A5 JP2024524222 A5 JP 2024524222A5 JP 2023578940 A JP2023578940 A JP 2023578940A JP 2023578940 A JP2023578940 A JP 2023578940A JP 2024524222 A5 JP2024524222 A5 JP 2024524222A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleoside
- complex according
- seq
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163212816P | 2021-06-21 | 2021-06-21 | |
| US63/212,816 | 2021-06-21 | ||
| PCT/US2022/033956 WO2022271543A2 (en) | 2021-06-21 | 2022-06-17 | Muscle targeting complexes and uses thereof for treating friedreich's ataxia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524222A JP2024524222A (ja) | 2024-07-05 |
| JP2024524222A5 true JP2024524222A5 (cg-RX-API-DMAC7.html) | 2025-06-25 |
Family
ID=84545809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578940A Pending JP2024524222A (ja) | 2021-06-21 | 2022-06-17 | 筋標的化複合体およびフリードライヒ運動失調症を処置するためのその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250099603A9 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4359008A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024524222A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118251238A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3222816A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022271543A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10517877B2 (en) * | 2016-03-30 | 2019-12-31 | Wisconsin Alumni Research Foundation | Compounds and methods for modulating frataxin expression |
| WO2019126641A2 (en) * | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
| AU2019315593B2 (en) * | 2018-08-02 | 2026-05-21 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| CA3108386A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating friedreich's ataxia |
| CN114025805B (zh) * | 2019-06-07 | 2025-01-24 | 达因疗法公司 | 制备蛋白质-寡核苷酸复合物的方法 |
| CN115427448A (zh) * | 2020-01-10 | 2022-12-02 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| AU2021313058A1 (en) * | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
-
2022
- 2022-06-17 CA CA3222816A patent/CA3222816A1/en active Pending
- 2022-06-17 US US18/572,321 patent/US20250099603A9/en active Pending
- 2022-06-17 WO PCT/US2022/033956 patent/WO2022271543A2/en not_active Ceased
- 2022-06-17 CN CN202280050965.4A patent/CN118251238A/zh active Pending
- 2022-06-17 EP EP22829057.3A patent/EP4359008A4/en active Pending
- 2022-06-17 JP JP2023578940A patent/JP2024524222A/ja active Pending